Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Progress towards a vaccine for schistosomiasis.

Edward J Pearce1

  • 1Department of Pathobiology, Room 203D, Johnson Pavilion, 3610 Hamilton Walk, University of Pennsylvania, Philadelphia, PA 19104-6076, USA. ejpearce@mailmed.upenn.edu

Acta Tropica
|May 15, 2003
PubMed
Summary

Developing a schistosomiasis vaccine is crucial for long-term control. While progress is being made with vaccines like Bilhvax, maintaining research momentum is vital to combat this widespread parasitic disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antigen-presenting cancer-associated fibroblasts in murine pancreatic tumors differentially regulate T-cell phenotype and function.

Journal of immunology (Baltimore, Md. : 1950)·2026
Same author

A STAT1/ETC/GBP1 axis represents a potential therapeutic target for noncommunicable granulomatous skin disease.

Science advances·2026
Same author

Cardiolipin preserves T<sub>reg</sub> metabolic fitness and immune homeostasis in the gut.

Nature metabolism·2026
Same author

IL-33 promotes transcriptional and metabolic adaptations of tissue-resident Th2 cells.

Journal of immunology (Baltimore, Md. : 1950)·2026
Same author

Monocytes are biological sensors of aging and frailty in humans.

bioRxiv : the preprint server for biology·2026
Same author

The transition from monocyte to tissue-resident macrophage requires DHPS.

Nature·2026

Area of Science:

  • Neglected tropical diseases
  • Vaccinology
  • Parasitic infections

Background:

  • Schistosomiasis remains a major global health challenge, particularly in Africa.
  • Mass drug administration for school-aged children is a current control strategy.
  • A protective vaccine offers a more sustainable long-term solution.

Purpose of the Study:

  • To review the current status of schistosomiasis vaccine development.
  • To highlight the importance of maintaining research momentum.
  • To discuss the potential of vaccines like Bilhvax.

Main Methods:

  • Literature review of schistosomiasis vaccine research.
  • Analysis of current control strategies and their limitations.
  • Assessment of vaccine candidates in development, including Bilhvax.

Related Experiment Videos

Main Results:

  • Schistosomiasis control relies on mass drug treatment, but a vaccine is preferable.
  • One vaccine candidate, Bilhvax, has reached Phase II clinical trials.
  • There is a risk of losing momentum in schistosomiasis vaccine research.

Conclusions:

  • Vaccine development is critical for the ultimate control of schistosomiasis.
  • Continued investment and focus are necessary to advance vaccine research.
  • Overcoming research momentum loss is key to achieving a protective schistosomiasis vaccine.